Lilly Drug Shows Survival Benefit In NSCLC, Raising Its Prospects
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Expectations for Eli Lilly’s ramucirumab were dampened after it failed in a Phase III trial in breast cancer patients, but enthusiasm for the drug has been reignited now that it demonstrated a survival benefit in one of oncology’s riskiest areas – lung cancer.
You may also be interested in...
Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial
Lilly’s necitumumab – gained through the company’s ImClone acquisition – demonstrates an overall survival benefit in the SQUIRE study against first-line metastatic squamous NSCLC. Pleasantly surprised by the outcome, some analysts start to expect blockbuster sales.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.